The Journal of Experimental Medicine
Avanti Polar Lipids, Inc.
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online May 26, 2008
doi:10.1084/jem.20072194
The Journal of Experimental Medicine, Vol. 205, No. 6, 1477-1490
The Rockefeller University Press, 0022-1007 $30.00
© 2008 Miedel et al.
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 4674K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miedel, M. T.
Right arrow Articles by Kiselyov, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miedel, M. T.
Right arrow Articles by Kiselyov, K.
Related Collections
Right arrowRelated In this Issue article
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

ARTICLE

Membrane traffic and turnover in TRP-ML1–deficient cells: a revised model for mucolipidosis type IV pathogenesis

Mark T. Miedel1, Youssef Rbaibi3, Christopher J. Guerriero1, Grace Colletti3, Kelly M. Weixel1, Ora A. Weisz1,2, and Kirill Kiselyov3

1 Renal-Electrolyte Division and 2 Department of Cell Biology and Physiology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261
3 Department of Biological Sciences, University of Pittsburgh, Pittsburgh, PA 15260

CORRESPONDENCE Ora A. Weisz: weisz{at}pitt.edu OR Kirill Kiselyov: kiselyov{at}pitt.edu

The lysosomal storage disorder mucolipidosis type IV (MLIV) is caused by mutations in the transient receptor potential–mucolipin-1 (TRP-ML1) ion channel. The "biogenesis" model for MLIV pathogenesis suggests that TRP-ML1 modulates postendocytic delivery to lysosomes by regulating interactions between late endosomes and lysosomes. This model is based on observed lipid trafficking delays in MLIV patient fibroblasts. Because membrane traffic aberrations may be secondary to lipid buildup in chronically TRP-ML1–deficient cells, we depleted TRP-ML1 in HeLa cells using small interfering RNA and examined the effects on cell morphology and postendocytic traffic. TRP-ML1 knockdown induced gradual accumulation of membranous inclusions and, thus, represents a good model in which to examine the direct effects of acute TRP-ML1 deficiency on membrane traffic. Ratiometric imaging revealed decreased lysosomal pH in TRP-ML1–deficient cells, suggesting a disruption in lysosomal function. Nevertheless, we found no effect of TRP-ML1 knockdown on the kinetics of protein or lipid delivery to lysosomes. In contrast, by comparing degradation kinetics of low density lipoprotein constituents, we confirmed a selective defect in cholesterol but not apolipoprotein B hydrolysis in MLIV fibroblasts. We hypothesize that the effects of TRP-ML1 loss on hydrolytic activity have a cumulative effect on lysosome function, resulting in a lag between TRP-ML1 loss and full manifestation of MLIV.


Abbreviations used: apoB, apolipoprotein B; CO, cholesteryl oleate; HA, hemagglutinin; LacCer, BODIPY-C5-lactosylceramide; LDL, low density lipoprotein; LPDS, lipoprotein-deficient serum; MLII, mucolipidosis type II; MLIV, mucolipidosis type IV; NPC, Niemann-Pick type C; TCA, trichloroacetic acid; TMR, tetramethylrhodamine; TRP-ML1, transient receptor potential–mucolipin-1.

© 2008 Miedel et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.jgp.org/misc/terms.shtml). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related In this Issue article

No exit strategy for lipids
Hema Bashyam
J. Exp. Med. 2008 205: 1247. [Full Text] [PDF]



This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS